EL
Therapeutic Areas
AnaptysBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANB033 | Celiac Disease (CeD) | Phase 1 |
| Rosnilimab | Rheumatoid Arthritis (RA) | Phase 1 |
| ANB101 | Inflammatory/Autoimmune Disease (BDCA2 modulation) | Phase 1 |
| Jemperli (dostarlimab-gxly) | Endometrial Cancer, Mismatch Repair-Deficient Solid Tumors | Approved |
| Imsidolimab | Generalized Pustular Psoriasis (and other inflammatory) | Phase 2/3 |
Leadership Team at AnaptysBio
DF
Daniel Faga
President & Chief Executive Officer
DM
Dennis Mulroy
Chief Financial Officer
PF
Paul F. Lizzul
Chief Medical Officer
BS
Ben Stone
Chief Business Officer
MD
Martin Dahl
Senior Vice President, Research
CS
Cailin Sibley
Senior Vice President, Translational Medicine
PR
Priya Raina
Senior Vice President, Clinical Operations
MD
Monique da Silva
Senior Vice President, Corporate Affairs
DM
David McKeon
Senior Vice President, Controller
BM
Beth Mueller
Senior Vice President, Human Resources